Pediatric Crohn’s Disease (pCD)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00
Despite the availability of current therapeutics, there remains the unmet need for more effective treatment to reduce the recurrence rate which is quite high. Emerging drugs like Mirikizumab (Eli Lilly and Company), Stelara (Janssen Research & Development, LLC), Entyvio(Takeda Oncology), and others are likely capable to eliminate the current challenges and also have the potential to drive the market size of pediatric Crohn’s Disease (pCD). The reduced cost of biosimilars relative to Pediatric Crohn’s disease can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.
Description
Pediatric Crohn’s Disease (pCD) is a rare condition commonly referred to as inflammatory bowel disease (IBD) which are immunologically mediated inflammatory diseases of the gastrointestinal tract occurring in children and adolescence. It typically affects the terminal ileum but can discontinuously affect the entire gastrointestinal tract and commonly leads to complications such as fistulas, abscesses, and stenosis. Although, there is no cure for Crohn’s disease, but with proper treatment and support the disease can be effectively managed and may go into remission for long periods of time.
In long-term, pediatric Crohn’s disease remains an attractive indication for drug development, with a rich clinical pipeline. Amid an increasingly competitive commercial landscape), we continue to view pediatric Crohn’s disease as an attractive indication for drug development; no therapy in development has demonstrated ‘game-changing’ or meaningfully differentiated efficacy, leaving room for new entrants to compete. Among earlier-stage mechanisms, physicians indicate enthusiasm for additional safe, effective oral agents and may theoretically drive greater efficacy in select patient populations.
Pediatric Crohn’s Disease (pCD) – Prevalence (Epidemiology)
Pediatric Crohn’s disease (pCD) is a rare, inflammatory bowel disease characterized by severe, chronic inflammation of the intestinal wall or any portion of the gastrointestinal tract. Crohn’s Disease is most common in individuals between 15-35, with approximately 25% diagnosed by age 20. The total prevalent cases in the G7 countries are anticipated to rise from XX in 2017 to 82,519 by 2030 at a CAGR of 2.1% for the study period (2017–2030)”
Pediatric Crohn’s Disease (pCD)– Current Market Size & Forecast Trends
The most widely used drugs in Crohn’s Disease are corticosteroids, immunosuppressants, and biologicals (anti-TNF, anti-interleukins, and anti-integrins). The landscape of pediatric Crohn’s disease (CD) is rapidly changing. Therapeutic advances seen in the adult arena are rapidly adopted by pediatric gastroenterologists and evaluated in both controlled studies and real-world experience. Additionally, pediatrics is leading the way as in a primary therapy which uses regimens including diet specific carbohydrate (SCD) and exclusive enteral nutrition (EEN). With the advent of the market entry of anticancer necrosis factor alpha (TNF-α) inhibitors, the market landscape has changed with more effective drugs with the potential for prolonged remission.
Report Highlights
- Pediatric Crohn’s Disease (pCD)– Current Market Trends
- Pediatric Crohn’s Disease (pCD)– Current & Forecasted Cases across the G7 Countries
- Pediatric Crohn’s Disease (pCD)– Market Opportunities and Sales Potential for Agents
- Pediatric Crohn’s Disease (pCD)– Patient-based Market Forecast to 2030
- Pediatric Crohn’s Disease (pCD)– Untapped Business Opportunities
- Pediatric Crohn’s Disease (pCD)– Product Positioning Vis-a-vis Competitors’ Products
- Pediatric Crohn’s Disease (pCD)– KOLs Insight
Additional information
| Price | 2-3 User License, Enterprise License, Single User License, Site User License |
|---|
Table of Contents
-
-
-
- Executive Summary
- Key Findings
- Pediatric Crohn’s Disease: Current and Emerging Trends
- Pediatric Crohn’s Disease Background
- Pediatric Crohn’s disease Definition
- Signs and Symptoms
- Causes
- Pathophysiology
- Diagnosis
- Epidemiology Estimated and Forecast to 2030
- Key Findings
- Methods and data Sources
- Country Specific Prevalent Cases of Pediatric Crohn’s Disease (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Treated Cases of Pediatric Crohn’s disease by Therapies
- Key Sources for Pediatric Crohn’s disease Epidemiology and Model Parameters
- United States
- United States Prevalent cases of Pediatric Crohn’s disease
- United States Treated Cases of Pediatric Crohn’s disease by Therapies
- Germany
- Germany Prevalent cases of Pediatric Crohn’s disease
- Germany Treated Cases of Pediatric Crohn’s disease by Therapies
- France
- France Prevalent cases of Pediatric Crohn’s disease
- France Treated Cases of Pediatric Crohn’s disease by Therapies
- Italy
- Italy Prevalent cases of Pediatric Crohn’s disease
- Italy Treated Cases of Pediatric Crohn’s disease by Therapies
- Spain
- Spain Prevalent cases of Pediatric Crohn’s disease
- Spain Treated Cases of Pediatric Crohn’s disease by Therapies
- United States
-
-
- United Kingdom
- United Kingdom Prevalent cases of Pediatric Crohn’s disease
- United Kingdom Treated Cases of Pediatric Crohn’s disease by Therapies
- Japan
- Japan Prevalent cases of Pediatric Crohn’s disease
- Japan Treated Cases of Pediatric Crohn’s disease by Therapies
- United Kingdom
-
- Current Therapies and Medical Practice
- Key Findings
- Treatment Guidelines
- Marketed Therapies Chapters
- Adalimumab (AbbVie/MedImmune)
- Infliximab (Janssen Biotech)
- Pentasa (Kyorin Pharmaceutical/Ferring Pharmaceuticals)-
- Unmet Needs
- Emerging Therapies
- Pipeline Overview
- Therapeutic Developments Pipeline for Pediatric Crohn’s Disease
- Product Analysis
- Mirikizumab (Eli Lilly and Company)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- Ustekinumab (Janssen Research & Development, LLC)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- Vedolizumab (Takeda Oncology)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- Ozanimod (Bristol Myers Squibb)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- Mirikizumab (Eli Lilly and Company)
- Product Analysis
- Emerging Therapies
-
- Product Analysis
- STAT-201 (Statera Biopharma, Inc. [Formerly Cytocom, Inc.)]
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- Etrolizumab (Genentech/Hoffmann-La Roche)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- SGX203 (Soligenix Inc.)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- CERC-002 (Avalo Therapeutics, Inc. (Formerly Cerecor Inc.))
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- STAT-201 (Statera Biopharma, Inc. [Formerly Cytocom, Inc.)]
- Product Analysis
-
-
-
-
- Alofisel (Takeda)
- Product Profile
- Clinical Development
- Thetanix (4d pharma)
- Product Profile
- Clinical Development
- RBX-2660 (Rebiotix/Ferring)
- Product Profile
- Clinical Development
- Alofisel (Takeda)
-
-
- Pediatric Crohn’s Disease- Cost Burden & Prescriptions survey
- Future Treatment Paradigm
- Pediatric Crohn’s Disease Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Annual Cost of Current & Emerging Therapies
- Market Outlook
- Key Findings
- Country Specific Market Forecast to 2030
- G7 total Market for Pediatric Crohn’s Disease 2020-2030 (USD Million)
- G7 total Market for Pediatric Crohn’s Disease by Therapies 2020-2030 (USD Million)
- Market Forecast by Country
- United States
- United States Market for Pediatric Crohn’s Disease 2020-2030 (USD Million)
- United States Market for Pediatric Crohn’s Disease by Therapies 2020-2030 (USD Million)
- Germany
- Germany Market for Pediatric Crohn’s Disease 2020-2030 (USD Million)
- Germany Market for Pediatric Crohn’s Disease by Therapies 2020-2030 (USD Million)
- France
- France Market for Pediatric Crohn’s Disease 2020-2030 (USD Million)
- France Market for Pediatric Crohn’s Disease by Therapies 2020-2030 (USD Million)
- Italy
- Italy Market for Pediatric Crohn’s Disease 2020-2030 (USD Million)
- Italy Market for Pediatric Crohn’s Disease by Therapies 2020-2030 (USD Million)
- Spain
- Spain Market for Pediatric Crohn’s Disease 2020-2030 (USD Million)
- Spain Market for Pediatric Crohn’s Disease by Therapies 2020-2030 (USD Million)
- United Kingdom
- United Kingdom Market for Pediatric Crohn’s Disease 2020-2030 (USD Million)
- United Kingdom Market for Pediatric Crohn’s Disease by Therapies 2020-2030 (USD Million)
- Japan
- Japan Market for Pediatric Crohn’s Disease 2020-2030 (USD Million)
- Japan Market for Pediatric Crohn’s Disease by Therapies 2020-2030 (USD Million)
- United States
- Market Drivers and Constraints
- What Factors Are Driving the Market for Pediatric Crohn’s Disease?
- What Factors Are Constraining the Market for Pediatric Crohn’s Disease?
- Executive Summary
- Appendix
-
-
You may also like…
-
Progressive Supranuclear Palsy (PSP) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Select optionsProgressive supranuclear palsy (PSP) treatment landscape reflects a huge unmet need, as it is quite dry and limited to symptomatic and supportive care, with no disease-modifying therapies. Emerging therapies like RT-001 (Retrotope), Fasudil (Woolsey), Ezeprogind (AlzProtect), Emeramide (EmeraMed) and Droxidopa (H. Lundbeck) has the potential to overcome the challenges associated with the current therapeutic options in future. Sales of these emerging therapies to treat Progressive Supranuclear Palsy (PSP) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2030 study period, adding an estimated value to a total $1.3 billion market by 2030.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
Related products
-
Eosinophilic Esophagitis (EoE)| Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00Select optionsThe Eosinophilic Esophagitis (EoE) report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Schizophrenia | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the Diagnosed prevalence Schizophrenia population will contribute to increasing sales in the therapy market over our forecast period. An estimated annual growth rate of 1.40% in the diagnosed Prevalent Schizophrenia population across the major pharmaceutical markets will contribute to increasing Schizophrenia therapy sales. In 2017, there were approximately XX million diagnosed cases of Schizophrenia in the major markets; we expect the number of cases will exceed XX million in 2030 owing to changes in population demographics and increasing cases of treatment resistant Schizophrenia.The continuous involvement of second-generation treatments for the Schizophrenia patients will contribute to the the overall growth of the Schizophrenia therapy market and The uptake of the emerging treatments will drive significant sales growth for the Schizophrenia market through 2030. -
Wet Age-related Macular Degeneration (wAMD)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the Prevalence wet-AMD population specifically in the elderly population will contribute to increasing sales in the wet-AMD therapy market over our forecast period. According to WHO, by 2050, the world’s population aged 60 years and older is expected to total 2 billion. The rise in the number of the elderly population is a major key driver to develop more safe and effective treatment for wet AMD. Thus, a huge increase in the market size of wet AMD is expected in the coming years. An estimated annual growth rate of 4% in the Prevalent wet-AMD population across the major pharmaceutical markets will contribute to increasing wet-AMD therapy sales. In 2019, there were approximately xx million prevalent cases of wet-AMD in the major markets; we expect the number of cases will exceed xx million in 2030 owing to changes in population demographics and increasing aged population